Fundraising FoxValenTx
Maple Grove, US · Delaware corporation · 2 known investors
Find your way into ValenTx
Sign up to see every warm intro you have to ValenTx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ValenTx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JP
JON PATRICK ST. GERMAINExecutive
DK
DAVID KRENNExecutive
JN
JOHANN NEISZExecutive
Board
ML
MARY LINCOLN CAMPBELLBoard director
MD
MITCHELL DANNBoard director
PA
BI
BOBBY I. GRIFFINBoard director
Investors · 2
Kaiser Permanente Ventureslisted by Kaiser Permanente VenturesSan Francisco · $2M – $5M
How we know: Kaiser Permanente Ventures's portfolio page · Not right? Tell us
SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20Mvia Paul LaViolette · board
How we know: SV Health Investors's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$19.7M disclosed across 3 rounds · 2014–2019
▶$2MraisedFeb 2019 · 3 investors · BiotechnologyRule 506(b)
▶$2MraisedFeb 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elling HalvorsonDirector
- Paul LaVioletteDirector
- Bobby GriffinDirector
- Jack AhrensDirector
- Jon St. GermainExecutive Officer, Director
- Offering amount
- $5.3M
- Amount sold
- $2M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.3MraisedAug 2018 · 32 investors · BiotechnologyRule 506(b)
▶$10.3MraisedAug 2018 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul LaVioletteDirector
- Bobby I. GriffinDirector
- Jon St. GermainExecutive Officer, Director
- Amount sold
- $10.3M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedSep 2015 · 21 investors · BiotechnologyRule 506(b)
▶$7.5MraisedSep 2015 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MARY LINCOLN CAMPBELLDirector
- MITCHELL DANNDirector
- JON PATRICK ST. GERMAINExecutive Officer
- DAVID KRENNExecutive Officer
- PAUL A. LAVIOLETTEDirector
- JOHANN NEISZExecutive Officer, Director
- BOBBY I. GRIFFINDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are ValenTx's investors?
- ValenTx's investors include Kaiser Permanente Ventures, SV Health Investors.
- How much funding has ValenTx raised?
- ValenTx has disclosed $19.7M raised across 3 rounds.
- Where is ValenTx headquartered?
- ValenTx is headquartered in Maple Grove, US.